Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2014-06-12 Earnings Release
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Umecrine Mood rapporterar preliminära data från en explorativ fas II-studie i premenstruell dysforiskt syndrom (PMDS)
Earnings Release Classification · 1% confidence The document is a press release dated June 12, 2014, from Umecrine Mood AB reporting preliminary data from an exploratory Phase II study for their drug candidate UC1010 regarding Premenstrual Dysphoric Disorder (PMDS). It details study design, primary endpoint failure, post-hoc analysis results, safety profile, and includes quotes from the CEOs of Umecrine Mood and Karolinska Development. This content—announcing clinical trial results and business updates—is characteristic of an Earnings Release (ER) or a general business update, but since it focuses purely on clinical trial results and business progress rather than comprehensive quarterly financials, it fits best under the general category of a business/operational announcement. Given the options, it is not a formal 10-K, IR, or AR. It is a specific operational update announcing results, which often precedes or accompanies an Earnings Release, but since it is a standalone announcement of results, 'ER' (Earnings Release) is the closest fit for a significant periodic business update, although 'RNS' (Regulatory Filings) is also plausible for non-standardized announcements. However, clinical trial result announcements are frequently categorized with ERs as they drive investor sentiment around performance. Given the focus on results and business progress, ER is selected over the generic RNS. FY 2014
2014-06-12 Swedish
Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder (PMDD)
Earnings Release Classification · 1% confidence The document is a press release dated June 12, 2014, announcing preliminary data from a Phase II clinical study for a drug candidate (UC1010) for PMDD. It details the study's primary endpoint outcome (not met), post hoc analysis results, safety profile, and includes quotes from the CEOs of Umecrine Mood and Karolinska Development. This content structure—announcing clinical trial results and business updates—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of financial/operational results (clinical trial outcome), it fits best under 'Earnings Release' (ER) as it serves the function of reporting key operational performance metrics to the market, even if it's not strictly quarterly financial figures. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP). Given the nature of reporting trial outcomes, ER is the most appropriate fit among the provided options for a significant operational update. FY 2014
2014-06-12 English
Dilaforette AB presenterar resultat från explorativ fas I/II-studie i okomplicerad malaria
Earnings Release Classification · 1% confidence The document is a press release dated May 30, 2014, announcing the results from an exploratory Phase I/II study of the drug candidate sevuparin for uncomplicated malaria by Dilaforette AB. It details the study's findings, safety profile, and future plans regarding severe malaria patients. This type of announcement, which releases key financial/operational results (clinical trial outcomes) to the public, aligns best with an Earnings Release (ER) or a general announcement. Since it is a specific operational update detailing results rather than just announcing that a report is available (which would be RPA/RNS), and it is not a full quarterly/annual report (10-K/IR), the most appropriate classification for a press release detailing operational performance/results is 'ER' (Earnings Release), as clinical trial results often serve as the primary 'earnings' driver for biotech/pharma companies. It is not a Call Transcript (CT) or a formal Investor Presentation (IP). Given the context of a company announcing specific operational results, ER is the best fit among the provided options. FY 2014
2014-05-30 Swedish
Dilaforette presents results from exploratory Phase I/II clinical trial in uncomplicated malaria
Regulatory Filings Classification · 1% confidence The document is a press release dated May 30, 2014, announcing the results of a clinical trial for the drug sevuparin in treating malaria. It details the study's objectives, findings (safety, tolerability, exploratory antiadhesive effects), and future plans (progressing to severe malaria studies). This type of announcement, which releases key operational and clinical development news, fits best under the 'Earnings Release' (ER) category if it were financial results, but since it is clinical trial results and strategic updates, it is a general corporate announcement. Given the options, it is not a formal regulatory filing like 10-K, a specific financial report (IR, AR), or a management discussion (MDA). It is an announcement of significant operational news. Since it is not a proxy statement (DEF 14A), dividend notice (DIV), or capital change (CAP/SHA), and it is not a transcript (CT) or presentation (IP), the most appropriate general category for a significant, non-financial, non-regulatory announcement of corporate progress is often the 'Regulatory Filings' (RNS) fallback, or potentially an 'Interim Report' (IR) if it were a comprehensive quarterly update. However, this is a specific press release about a clinical trial outcome. In the context of financial databases, press releases announcing trial results are often categorized as general corporate news or sometimes grouped with Earnings Releases if they are periodic. Given the strong focus on clinical development progress rather than financial performance, and lacking a better fit, 'RNS' (Regulatory Filings/General Announcement) is the safest fallback for a press release that doesn't fit the specific financial/governance codes. It is definitely not a Report Publication Announcement (RPA) because it contains the full substance, not just a notice that a report is attached.
2014-05-30 English
Karolinska Developments årsstämma 2014
AGM Information Classification · 1% confidence The document is titled 'Karolinska Developments årsstämma 2014' (Annual General Meeting 2014) and details the resolutions passed by the shareholders on May 14, 2014. Key decisions mentioned include the approval of financial statements, dividend disposition, granting of discharge to the board, election of board members and auditor, and approval of remuneration guidelines and stock programs. These contents are characteristic of the formal proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2014-05-15 Swedish
Karolinska Development´s Annual General Meeting 2014
AGM Information Classification · 1% confidence The document explicitly states in the title and opening paragraph that it contains the resolutions passed at the 'Annual General Meeting 2014' held on May 14, 2014. The content details specific resolutions regarding profit allocation, discharge from liability, election of directors and auditors, fees, and shareholder authorizations. This content perfectly matches the definition of AGM Information.
2014-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.